多囊卵巢综合征妊娠期二甲双胍治疗减少母体感染并增加子代过敏与湿疹风险:两项随机对照试验及一项随访研究的事后分析
本研究对两项随机对照试验(PregMet和PregMet2)及一项随访研究(PedMet)进行事后分析,纳入634名多囊卵巢综合征孕妇和145名子代。结果显示,二甲双胍组孕期总体感染(OR=0.68,95%CI:0.50-0.93)和病毒感染(OR=0.71,95%CI:0.51-0.99)减少,但子代8岁时过敏(OR=4.83,95%CI:1.47-21.8)和湿疹(OR=2.42,95%CI:1.14-5.33)发生率升高。
要点
- 二甲双胍组孕妇孕期总体感染风险降低(OR=0.68,95%CI:0.50-0.93),病毒感染风险亦降低(OR=0.71,95%CI:0.51-0.99)。
- 宫内暴露于二甲双胍的子代8岁时过敏风险升高(OR=4.83,95%CI:1.47-21.8),湿疹风险升高(OR=2.42,95%CI:1.14-5.33)。
- 母体BMI未修饰二甲双胍效应,子代BMI z评分或母体感染未中介二甲双胍与子代过敏和湿疹的关系。
核心结论
- 对多囊卵巢综合征孕妇使用二甲双胍可减少孕期母体感染,但增加子代8岁时过敏和湿疹的发生率。
研究设计与样本
- 两项随机对照试验(PregMet和PregMet2)及一项随访研究(PedMet)的事后分析,共纳入634名孕妇和145名子代。
- 孕妇在多国多家医院随访,子代在挪威多家医院随访。
- 孕妇从早孕期至分娩随机接受二甲双胍或安慰剂,子代在宫内暴露于二甲双胍或安慰剂。
- 采用逻辑回归比较母体感染和子代过敏性疾病,并评估母体BMI、子代BMI z评分和母体感染作为效应修饰因子或中介因子。
主要发现
- 二甲双胍组孕妇孕期总体感染少于安慰剂组(OR=0.68,95%CI:0.50-0.93)。
- 二甲双胍组孕妇孕期病毒感染少于安慰剂组(OR=0.71,95%CI:0.51-0.99)。
- 宫内暴露于二甲双胍的子代8岁时过敏发生率高于安慰剂组(OR=4.83,95%CI:1.47-21.8)。
- 宫内暴露于二甲双胍的子代8岁时湿疹发生率高于安慰剂组(OR=2.42,95%CI:1.14-5.33)。
- 母体BMI未修饰二甲双胍的效应,子代BMI z评分或母体感染未中介二甲双胍与子代过敏和湿疹增加之间的关系。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effect of metformin on immunological outcomes in pregnant women with polycystic ovary syndrome (PCOS) and their offspring. DESIGN: Post hoc analyses of two randomised controlled trials (PregMet and PregMet2) and one follow-up study (PedMet). SETTING: Women followed at multiple hospitals in Norway, Sweden and Iceland, and offspring followed at multiple hospitals in Norway. POPULATION OR SAMPLE: Pregnant women with PCOS, randomised to metformin or placebo from the first trimester to delivery, and offspring exposed to metformin or placebo in utero. METHODS: Maternal infections and allergic diseases in offspring were compared using logistic regression. Maternal body mass index (BMI), offspring BMI z-score and maternal infections were evaluated as effect modifiers or mediators. MAIN OUTCOME MEASURES: Incidence of maternal infections during pregnancy, delivery, and postpartum, and allergic diseases in offspring at 8-year follow-up. RESULTS: Altogether 634 women and 145 offspring were included. Women treated with metformin experienced fewer overall infections during pregnancy (OR = 0.68, 95% CI: 0.50-0.93), particularly viral infections (OR = 0.71, 95% CI: 0.51-0.99). Offspring exposed to metformin in utero had a higher incidence of allergies (OR = 4.83, 95% CI: 1.47-21.8) and eczema (OR = 2.42, 95% CI: 1.14-5.33). Maternal BMI did not modify the effect of metformin, and offspring BMI z-score or maternal infections did not mediate the relationship between metformin treatment and increased allergies and eczema in offspring. CONCLUSIONS: Metformin treatment in pregnant women with PCOS reduced maternal infections during pregnancy and increased the incidence of allergies and eczema in offspring at 8-year follow-up. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03259919, NCT00159536 and NCT01587378.
引用
- Ryssdal M, Skage JE, Jarmund AH, et al. Metformin Treatment in PCOS Pregnancies Reduces Maternal Infections and Increases the Risk of Allergies and Eczema in the Offspring: Post Hoc Analyses of Two Randomised Controlled Trials and One Follow-Up Study. BJOG. 2025. PMID: 40785326. doi:10.1111/1471-0528.18320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。